RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $95 to $100.